IFF and Universidad Católica San Antonio de Murcia Research Demonstrates AB-Fortis® Delivers Better Iron Tolerability

Rhea-AI Summary

IFF (NYSE: IFF) announced research with UCAM showing that its AB-Fortis^® iron ingredient is better tolerated than traditional iron salts. The microencapsulated iron, derived from natural alginate, minimizes gastrointestinal discomfort and enhances absorption. This technology addresses common issues faced by users of iron supplements, especially vegetarians and vegans. A clinical study indicates significant tolerability advantages over ferrous sulfate, with fewer side effects. The ingredient's high iron content allows small dosages without affecting taste.

Positive

• AB-Fortis^® shows improved tolerability compared to ferrous sulfate, as per recent clinical study.
• The microencapsulated iron is suitable for vegetarians and vegans, widening its market appeal.
• Significant reduction in gastrointestinal side effects helps improve user compliance.

Negative

• None.

NEW YORK, Dec. 6, 2022 /PRNewswire/ -- IFF (NYSE: IFF) has unveiled research in partnership with the Universidad Católica San Antonio de Murcia (UCAM), demonstrating that the AB-Fortis^® iron ingredient is significantly better tolerated than a common iron salt. AB-Fortis^® is an iron salt encapsulated in alginate—a natural seaweed-derived polysaccharide—making the ingredient appropriate for vegetarians and vegans. This unique encapsulation technology is particularly robust under high pressure and temperature during processing. AB-Fortis^® maintains its encapsulation in the stomach to avoid triggering gastrointestinal (GI) discomfort, and then releases iron in the intestine for optimal absorption.

Globally, iron deficiency is a pervasive health concern^[1]. The need for iron supplementation has increased due to the prevalence of conditions such as celiac disease, irritable bowel syndrome (IBS), chronic kidney and heart diseases, and the growing adoption of vegetarian and vegan lifestyles. Iron supplementation compliance can be a challenge due to low bioavailability and its potential side effects, which may include metallic taste and gastrointestinal discomfort.

In a study published in the International Journal of Molecular Sciences and funded by IFF, results suggest that the consumption of an iron supplement in the formulation of a microencapsulated ferric preparation (MFS) is associated with a better tolerability profile when compared to ferrous sulphate (FS), a commonly used iron supplement. The single-center, crossover, randomized, double-blind, and controlled clinical study investigating the effect of MFS on healthy pre-menopausal women demonstrates that AB-Fortis^® is very well tolerated, even at a relatively high dose of 60 milligrams of elemental iron. It has significantly fewer GI side effects such as constipation, diarrhea, nausea and epigastric distress than FS^[2].

"We're pleased to partner with UCAM in this research to demonstrate that our premium iron ingredient, AB-Fortis^® has excellent oral tolerability," said Ryan Lauchli, global health category manager, IFF Health. "Iron can be hard to tolerate for many who take supplements, but our natural encapsulation is a great solution for our customers to incorporate into many different dietary supplements and food formats. We are proud to be able to deliver an efficacious ingredient to the industry so consumers can benefit."

This microencapsulated iron is produced using a unique patented technology. It is protected by an organic layer that minimizes the release of free iron into the food and does not produce a metallic taste. The 40 percent high iron content in the microcapsule allows it to be used in small dosages, and does not change the appearance, palatability or taste of fortified foods.

To learn more about IFF Health and AB-Fortis^® visit www.iff-health.com.

[1] World Health Organization. Anaemia.

[2] Friling, M. et al. Tolerability of Oral Supplementation with Microencapsulated Ferric Saccharate Compared to Ferrous Sulphate in Healthy Premenopausal Woman: A Crossover, Randomized, Double-Blind Clinical Trial. Int. J. Mol. Sci. 2022, 23(20), 12282

Welcome to IFF

At IFF (NYSE: IFF), an industry leader in food, beverage, health, biosciences and scent, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com, Twitter , Facebook, Instagram, and LinkedIn.

©2022 International Flavors & Fragrances Inc. (IFF). IFF, the IFF Logo, and all trademarks and service marks denoted with ™, ^SM or ® are owned by IFF or affiliates of IFF unless otherwise noted. All Rights Reserved.

Contact: 
Victoria Oldridge
Global Communications Specialist
+1 415-307-2164
Victoria.Oldridge@iff.com 

SOURCE IFF

FAQ

What is AB-Fortis® by IFF?

AB-Fortis® is a microencapsulated iron ingredient that offers better tolerability compared to traditional iron salts, making it suitable for various dietary supplements.

What recent research has IFF conducted regarding iron supplementation?

IFF partnered with UCAM to demonstrate that AB-Fortis® is better tolerated and has fewer gastrointestinal side effects than ferrous sulfate.

What are the benefits of using AB-Fortis® for iron supplementation?

AB-Fortis® reduces gastrointestinal discomfort, enhances iron absorption, and is suitable for vegetarians and vegans.

When was the IFF press release about AB-Fortis® published?

The press release was published on December 6, 2022.

How does AB-Fortis® improve iron supplementation compliance?

By minimizing gastrointestinal side effects and allowing for smaller dosages without altering the taste of food.